Renal Denervation for Hypertension: From Innovation to Indication

Raymond R Townsend1, Michael A Weber2

  • 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Insights

Uncontrolled high blood pressure affects many adults globally. Emerging therapies like renal denervation, administered in clinical settings, show promise for improving blood pressure control and adherence.

Area of Science:

  • Cardiology
  • Nephrology
  • Public Health

Background:

  • Hypertension remains a significant global health challenge, with a substantial portion of adults exhibiting uncontrolled blood pressure despite established treatments.
  • Treatment nonadherence is a key barrier to achieving blood pressure control, necessitating novel therapeutic strategies.
  • Established interventions like medication and lifestyle modifications have limitations in widespread efficacy.

Discussion:

  • This special issue introduces advancements in hypertension management, focusing on device-based therapies and novel agents like silencing ribonucleic acids.
  • These newer approaches demonstrate high efficacy and circumvent adherence issues due to their administration within healthcare settings.
  • The historical context and current epidemiology of hypertension underscore the public health imperative for improved blood pressure management.

Key Insights:

  • Emerging therapies, including renal denervation, offer high efficacy in lowering blood pressure.
  • In-office administration of new treatments enhances patient adherence compared to traditional methods.
  • Optimizing blood pressure control is crucial for preventing target organ damage associated with hypertension.

Outlook:

  • Future research will explore patient selection criteria for renal denervation.
  • Efficacy, success measurement, and procedural guidance for renal denervation will be detailed.
  • Renal denervation represents a promising emerging therapy for managing resistant hypertension.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
334
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
458
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
590
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
284
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
413
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
441